Introduction
Gliomas in adults are devastating diseases, with very poor survival despite their lack of distant metastases.
The best avaiable treatments, such as surgical resection and radiotherapy have been only temporarly successful, once recidives are almost always present, being fatal within 1 to 2 years of onset of first symptoms.
Two factors promoting the use of gene therapy for gliomas are the failure and toxicity of conventional theraHigh-grade gliomas are relatively frequent in adults and consist in the most malignant form of primary brain tumor. They are resistant to standard treatment modalities such as surgery, radiation, and chemotherapy, being fatal within 1 to 2 years of onset of symptoms. Owing to the promising practical clinical benefits that can be expected for the near future, an exposition of the basic issues in genetic therapy of gliomas seems timely. In this article we intend to provide a general review that covers the most important genes already studied as possible agents for genetic therapy in gliomas. In a critical analysis we intend to expose and discuss anti-tumoral mechanisms and therapeutical results of studies with the following class of genes: prodrug activation systems, apoptosis-related genes, anti-angiogenic factors genes, radiosensitization genes, chemosensitization genes, apoptosis-related genes and immunogenes. Finally we discuss the historical importance, actual role and further developments that can be expected from each of these class of agents for the future of genetic therapy of gliomas. Microbial genes (e.g. herpes simplex virus thymidine kinase) may be transferred into the tumors allowing for prodrug activation (e.g. ganciclovir). Furthermore, that frequently involves ex vivo transfection of autologous tumor cells with such genes. [1] Malignant gliomas have been chosen for the first clini-cal studies on novel gene therapy approaches because these tumors are non-metastatic and develop on the largely postmitotic background of normal glial and neuronal tissue. Several molecular strategies have been tested, either in animal models or clinical trials: prodrug activating systems, introduction of tumor suppressor or cell-cycle-related genes, inhibition of growth factors and/ or their receptors, inhibition of neovascularization, immunomodulatory maneuvers, oncolytic viruses, inhibition of matrix metalloproteinases, induction of local expression of toxic agents and sensitization of tumors to chemotherapeutic agents and radiotheraphy. [2, 3] Critical evaluation of gene transfer and therapy studies has led to the conclusion that, even using identical vectors, the anatomical route of vector can dramatically affect both the efficiency of tumor transduction and its spatial distribution, as well as the extent of intratumoral and intracerebral transgene expression. The safety and efficiency of these therapeutic systems in humans have been availed by several controlled preclinical and clinical therapeutic trials. [4] [5] [6] 
Genes

Prodrug Activation Systems HSV-TK/Ganciclovir
Tumor cell transduction with herpes simplex virus thymidine kinase (HSV-TK) gene and treatment with ganciclovir (GCV) is the more widely studied cancer gene therapy. [7] [8] [9] [10] [11] HSV-TK converts the pro-drug ganciclovir (GCV) into a toxic nucleotide analogue, the incorporation of which into cellular DNA blocks cell proliferation. Following repetitive ganciclovir (GCV) intraperitoneal or intravenous injection, effective killing of glioma cells in mouse brain is observed [ Figure 1 ]. In vivo studies relate a significant regression of the tumors in 50-80% of the rats treated with this therapy modality as compared with control animals. In some animals tumors completely disappeared after this treatment protocol and mice were considerated are completely cured. [12] [ Figure cyclophosphamide. [17] More prolonged and higher concentrations of activated metabolites are generated by intraneoplastic injection compared with systemic administration of prodrug. [18] Na+/I-symporter
Radioiodide concentrating activity in the thyroid, mediated by human Na+/I-symporter (hNIS), provides a mechanism for effective radioiodide treatment for patients who have invasive, recurrent, and metastatic thyroid cancers after total thyroidectomy.
Some attempts to develop hNIS gene transfer for radioiodide therapy in patients with malignant glioma have been tried. Altough more in vivo research is necessary, tumoral hNIS transduction through adenovirus vector followed by radioiodide therapy is a modality of genetic therapy that promisses to have great progress in the next years. [19] Folylpolyglutamyl synthetase The results suggest that FPGS gene delivery enhances the antifolate sensitivity of some glioma cell lines. However this approach still need further evaluation as a therapeutic strategy. [20] Anti-angiogenic factors
Inhibition of angiogenesis has been considered among the most promising approaches to treat highly vascularized solid tumors such as high-grade gliomas.
However chronic systemic delivery of therapeutic proteins, such as inhibitors of angiogenesis, present a number of difficult pharmacological challenges. The concept that targeted antiangiogenesis, using virally mediated gene transfer, represents a promising strategy for delivering this antiangiogenic factors. [21] Angiostatin, Endostatin, and IFN-alpha ( These findings suggest that the FADD gene is a novel and useful tool for the treatment of malignant gliomas. [27] Other apoptosis-related genes Some studies suggest that adenoviral vector-mediated delivery of other apoptosis-related genes may be also potentially useful in the gene therapy approach toward the treatment of human brain gliomas. Apoptosisrelated genes already studied are caspase-8, p33ING1, p73alpha, Bax, Apaf-1, caspase-9, IkappaBdN, NFkappaB, caspase-3, gas-1, Bcl-2, and Bcl-X(L). [28, 29] Immunogenes Cancer immunogene therapy is based on vaccination with radiated, autologous tumor cells transduced with immunostimulatory genes. Several cytokines have been studied wheter as vaccine ex vivo transfection Genetic therapy in gliomas models or the classic in situ inoculation of the vector modified to carry the cytokine gene. [30] [31] [32] The vaccination treatment using tumor cells geneti- [ 33] Several cytokines have been studied: IL-12, IL-6, IL-4, IL-18, IFN-gamma, TGF-beta, TNF-alpha, GM-CSF, B7-2, TNF-alpha, LIF and LT. [34] [35] [36] [37] In conclusion, genetic immunothearpy has shown to be a promising potential both for treatment of established intracranial glioma through potentiatinon of antitumor immunity of the patient and for vaccination against subsequent intracranial glioma cell implantation.
Chemosensitization genes
Cell cycle regulator WAF1/Cip1
Studies have shown that the negative cell cycle regu- These results confirms that Ad/Bax synergistically radiosensitizes glioma, with a seemingly favorable therapeutic index. [40] p53 gene It was demonstrated that RT2 tumour cells express native rat wild-type p53 before the transduction and markedly overexpressed human p53 following adenoviral p53 transduction. P53 transduction followed by radiation resulted in marked decreases in RT2 cell survival and a increase in apoptosis at radiation doses from 2 to 6 Gy. Animals receiving cranial radiation after intracerebral implantation with RT2 cells previously transduced with p53 survived significantly longer than control animals. [41] These results support a new perspective in the p53 genetic therapy, showing the ability to enhance the radiosensitivity of malignant glioma cells that express wild-type p53 by using adenoviral transduction to induce overexpression of p53. This offers new hope for the p53 viral mediated genetic therapy as a sucessful therapeutic strategy, not only in human gliomas that express mutant p53, but also in those that express wild-type p53.
Cytokines
Some cytokine vaccination (GM-CSF, IL-4, IL-12)
therapies have shown to have not only primary immunity generation against the tumour, but also an important radiosensitization effect. In some studies with tumors treated with vaccination therapy and posteriorly irradiation, about 80-100% of the glioma-bearing mice was cured. [42] [43] [44] Other genes
Carcinoembryonic antigen (CEA)
CEA has potent antitumor activity against gliomas in vitro, as well as in orthotopic U87 animal models. showed total regression of the glioma by magnetic resonance imaging (MRI) and do not showed other appreciable toxic effects. [47] 
Clinical Trials
The most studied candidates for gene therapy, is presented. [48] The most advanced study with p53 gene is a phase There is a ongoing phase I/II clinical study in adult patients with recurrent high-grade glioma which aimed to evaluate biological safety, maximum tolerated dose and antitumor efficacy of a cytokine vacination model, using a genetically modified replication-disabled Semliki forest virus vector (SFV) that carries the human interleukin 12 (IL-12) gene. [50] Several other Phase I and II clinical studies in patients with recurrent malignant glioma have shown a favorable safety profile and some efficacy of retroviruses (RV) mediated gene therapy. [51] More than 300 patients with glioma have been already treated in clinical trials with oncolytic viruses, and in most cases virus was administered directly into the tumor. Furthermore, clinical studies did not address main limiting factors for in vivo gene therapy, such as insufficient gene transfer rates to the tumor with used local delivery modalities, and resulting inability of a particular transgene-prodrug system to confer permanently eradicating cytotoxicity to the whole neoplasm.
The ultimate molecular therapy will probably involve the application of multiple simultaneous (combinatorial) therapeutic modalities.
